ZEVRA THERAPEUTICS, INC. ZVRA
We are a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. We are focused on expanding patient access, progressing our pipeline toward key milestones, and delivering meaningful therapeutics. Our vision is realized through disciplined execution of our strategic plan and our core values — patient centricity, integrity, accountability, innovation, and courage — which guide our efforts to deliver long-term value. The commercialization of our lead product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and demonstrates our ability to advance therapies from development to market.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106.5M | $23.6M | $27.5M | $10.2M | $28.6M | $13.3M | $12.8M | $0 | — | — |
| Cost of revenue | — | — | $2.9M | $222.0K | $2.1M | — | $10.0M | $0 | — | — |
| Gross profit | — | — | $24.5M | $9.9M | $26.6M | — | $2.8M | $0 | — | — |
| R&D | — | — | — | — | $10.2M | $8.8M | $19.4M | $41.8M | $20.6M | $20.5M |
| SG&A | $77.6M | $54.9M | $34.3M | $15.0M | $8.7M | $7.9M | $10.8M | $12.5M | $12.8M | $14.0M |
| Total operating expenses | $90.4M | $97.0M | $74.1M | $52.7M | $20.9M | $18.9M | $33.2M | $55.9M | $33.4M | $37.5M |
| Operating income | -$62.9M | -$87.0M | -$49.6M | -$42.6M | $7.7M | -$5.6M | -$20.3M | -$55.9M | -$33.4M | -$37.5M |
| Interest expense | $8.0M | $7.4M | $1.5M | $335.0K | $226.0K | $4.8M | $4.9M | $5.5M | $5.8M | $5.5M |
| Pre-tax income | $86.7M | -$90.1M | -$46.0M | -$26.8M | -$8.5M | -$12.8M | -$24.5M | -$56.6M | -$43.4M | -$16.5M |
| Income tax | $3.4M | $15.4M | $0 | $33.0K | $34.0K | $34.0K | $22.0K | $126.0K | $43.0K | $15.0K |
| Net income | $83.2M | -$105.5M | -$46.0M | -$26.8M | -$8.6M | -$12.8M | -$24.5M | -$56.5M | -$43.4M | -$16.5M |
| EPS, basic | 1.40 | -2.28 | -1.30 | -0.78 | -2.11 | -3.21 | — | — | — | — |
| EPS, diluted | 1.35 | -2.28 | — | — | -2.11 | -3.21 | -13.23 | -3.15 | -2.96 | -1.13 |
| Shares, diluted (wtd. avg.) | 57.3M | 46.3M | 35.5M | 34.5M | 29.8M | 4.0M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $62.4M | $33.8M | $43.0M | $65.5M | $112.3M | $4.2M | $3.2M | $18.4M | $10.9M | $16.8M |
| Short-term investments | $128.6M | $35.7M | $24.7M | $16.9M | $0 | — | — | $3.3M | $31.4M | $51.0M |
| Receivables | — | $10.2M | $16.1M | $7.2M | $1.4M | $2.4M | $1.7M | $0 | $2.0M | $5.0M |
| Inventory | $1.7M | $2.0M | $0 | $671.0K | — | — | — | — | — | — |
| Total current assets | $223.0M | $86.0M | $86.9M | $92.8M | $115.1M | $8.4M | $7.0M | $23.7M | $45.9M | $74.4M |
| Property, plant and equipment | $489.0K | $356.0K | $736.0K | $794.0K | $884.0K | $1.0M | $1.5M | $1.8M | $2.0M | $2.0M |
| Goodwill | $4.7M | $4.7M | $4.7M | $0 | — | — | — | — | — | — |
| Other intangibles | $6.4M | $69.0M | $69.2M | $0 | — | — | — | — | — | — |
| Total assets | $284.7M | $178.1M | $172.3M | $115.3M | $132.9M | $11.2M | $10.5M | $26.7M | $52.5M | $84.9M |
| Accounts payable | $2.5M | $13.1M | $14.0M | $3.6M | $516.0K | $1.2M | $1.1M | $3.7M | $2.2M | $469.0K |
| Total current liabilities | $39.3M | $34.1M | $73.7M | $12.0M | $4.2M | $7.5M | $5.4M | $12.0M | $11.5M | $6.6M |
| Long-term debt | $61.9M | $59.5M | $5.1M | — | — | $67.7M | $77.3M | $81.4M | $92.7M | — |
| Total liabilities | $130.1M | $138.5M | $110.5M | $40.2M | $5.8M | $77.6M | $85.0M | $93.3M | $110.0M | $103.6M |
| Retained earnings | -$422.1M | -$505.3M | -$399.8M | -$353.7M | -$267.0M | -$258.5M | -$245.7M | -$221.2M | -$164.7M | -$121.3M |
| Total equity | $154.7M | $39.7M | $61.9M | $75.1M | $101.7M | -$66.4M | -$74.5M | -$66.6M | -$57.5M | -$18.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.6M | -$69.7M | -$33.5M | -$18.7M | $10.4M | -$1.9M | -$23.7M | -$54.2M | -$33.1M | -$29.8M |
| Depreciation and amortisation | $4.1M | $6.4M | $1.0M | $944.0K | $257.0K | $273.0K | $304.0K | $324.0K | $336.0K | $175.0K |
| Stock-based compensation | $12.6M | $14.9M | $6.0M | $4.3M | $2.4M | $2.5M | $4.4M | $6.5M | $4.6M | $6.6M |
| Capital expenditure | $835.0K | $0 | $296.0K | $93.0K | $102.0K | $33.0K | $26.0K | $21.0K | $181.0K | $643.0K |
| Investing cash flow | $18.1M | -$22.2M | -$17.4M | -$36.7M | -$15.5M | -$33.0K | $3.2M | $33.3M | $27.4M | -$45.8M |
| Financing cash flow | $12.1M | $82.1M | $28.5M | $8.4M | $113.1M | $2.7M | $4.9M | $28.0M | -$203.0K | $61.2M |
| Buybacks | — | $0 | $3.4M | $4.7M | $2.8M | $0 | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001434647-26-000025.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $12.8M | $13.3M | $28.6M | $10.2M | $27.5M | $23.6M | $106.5M |
| Gross profit | — | — | $0 | $2.8M | — | $26.6M | $9.9M | $24.5M | — | — |
| Net income | -$16.5M | -$43.4M | -$56.5M | -$24.5M | -$12.8M | -$8.6M | -$26.8M | -$46.0M | -$105.5M | $83.2M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |